key: cord-1045818-1fdnbq1f
authors: Swift, Melanie D; Breeher, Laura E; Tande, Aaron J; Tommaso, Christopher P; Hainy, Caitlin M; Chu, Haitao; Murad, M Hassan; Berbari, Elie F; Virk, Abinash
title: Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel
date: 2021-04-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab361
sha: 26ba6eb61c5ab2f26d27bcbfccd1ab8aeadd56b1
doc_id: 1045818
cord_uid: 1fdnbq1f

In a large cohort of US healthcare personnel (HCP) without prior COVID-19 infection, 94,382 doses of mRNA COVID-19 vaccine were administered to 49,220 individuals. The adjusted vaccine effectiveness following two doses of each of the two available brands of mRNA vaccine exceeded 96%.

Healthcare personnel are among the highest risk workers for COVID-19 (1) . In early December 2020, the Centers for Disease Control and Prevention (CDC) recommended that HCP be the first occupational group prioritized to receive newly authorized COVID-19 vaccines in the US (2) . By mid-December, two mRNA vaccines had received emergency use authorization (EUA) by the Food and Drug Administration (FDA), both of which demonstrated approximately 95% efficacy against symptomatic COVID-19 in clinical trials (3, 4) . We aim to provide an estimate of vaccine effectiveness (VE) in the subpopulation of HCP reached through employer vaccination programs, to enrich the rapidly growing body of evidence in this area (5) (6) (7) .

The Mayo Clinic consists of main campuses in Minnesota, Florida and Arizona, and a healthcare system spanning southern Minnesota and western Wisconsin, employing approximately 76,000 healthcare personnel (HCP). All actively employed HCP with a positive molecular assay for SARS-CoV-2 are contacted by Occupational Health Services (OHS) for systematic index case interview and contact tracing as described elsewhere (8) . Test results, exposure investigation details, vaccination status and employee demographics are included in the OHS record. Diagnostic molecular assays are conducted for any new COVID-19 symptom. In addition, asymptomatic HCP are tested serially for long term care facility surveillance, for 2 weeks following COVID-19 exposure at work or in the community, and a variety of other reasons such as anticipated personal travel or medical procedures. Social distancing, universal masking, and eye protection in patient care areas were required at all sites. Public mask mandates were in place in the communities of operation throughout most of the study period. We conducted a retrospective review of all HCP newly diagnosed with COVID-19 from 1/1/2021 to 3/31/2021. During this timeframe, two-week COVID-19 incidence rates expressed in new cases per 10,000 population, A c c e p t e d M a n u s c r i p t 5 dropped from 48.2 to 30.9 in Minnesota and from 73.2 to 14.8 in Wisconsin, both states in which the organization has multiple sites spread across a large geographic area. Two-week incidence rates for Duval County, Florida and Maricopa County, Arizona, home to the southern Mayo Clinic sites, fell from 126.6 to 17.3 and from 188 to 6.6, respectively. Regional incidence rates were extracted from the Johns Hopkins Coronavirus Resource Center (9) .

The employee COVID-19 vaccination program launched in December 2020, in close collaboration with state and local public health, vaccinating HCP in a staged fashion, prioritized by occupational risk in a process described previously (10) . 

The number of at-risk days for each employee was defined as any day in the study period prior to a positive test or the end of the observation period for uninfected individuals. We used the incidence rate for unvaccinated employees as a reference. We calculated the crude and adjusted incidence rate ratio (IRR) and exact 95% confidence interval (CI) and defined vaccine effectiveness (VE) as 1-IRR (11) The median age in the entire population was 41 years. Compared to unvaccinated individuals, fully vaccinated HCP were older, more likely to be white, Asian, or male, and more likely to have a job with direct patient contact (Table 1) . Fully vaccinated individuals were more likely to have had Pfizer/BioNTech than Moderna vaccine compared to partially vaccinated HCP. Among individuals with a positive SARS-CoV-2 test during the study, unvaccinated individuals were more likely to report symptoms.

After adjusting for age, gender, region, job, and week of vaccination, VE for partial and complete vaccination with each of the two available brands of mRNA exceeded 78% and 96%, respectively (Table 1 .)

We found an extremely high estimate of vaccine effectiveness in this large cohort of HCP at multiple US sites, with an adjusted VE over 96% for both available brands of mRNA vaccine.

This study adds to the limited evidence that is currently available regarding the impact of the COVID-19 vaccine on asymptomatic SARS-CoV-2 infection. Our results are similar to a large, case-control study that found a 94% reduction in symptomatic infection and 90% reduction in asymptomatic infection 7 or more days after the second dose of the Pfizer/BioNTech vaccine (6) . Our VE estimates are higher than those reported by a prospective cohort in UK HCP (7).

Our study is subject to several limitations. The most critical one is the lack of randomization and the likelihood of confounding. Since vaccination was voluntary, unmeasured personal and/or behavioral differences which exist between HCP who opted to take vaccine compared to those who did not may have introduced additional bias. Vaccinated HCP may be more compliant with precautions such as A c c e p t e d M a n u s c r i p t 8 masking and social distancing which would bias VE upwards. Alternatively, it is also possible that vaccinated individuals may have relaxed other precautions due to lower perceived infection risk, which could bias VE in the opposite direction. Additional confounders that could bias the estimate of VE upwards include the possibility that vaccinated HCP may be less likely to seek testing for minor symptoms, or to report unprotected exposures; and variation of infection intensity over time during the 3 month period of this study. This cohort consists of employed HCP with a median age of 41 years which is considerably younger than the median age of 51 to 53 years among subjects in the phase 3 vaccine trials which may in part explain differences in VE (3, 4) . In addition, there were too few asymptomatic infections in this cohort to evaluate how symptom status moderated VE. Maximal immune response to vaccination is attained at different times for the different vaccine formulations, however the number of events (positive cases) was small and did not allow estimation of VE at various intervals.

Vaccination is the single most promising tool to bring about widespread immunity and end the COVID-19 pandemic. Widespread uptake is crucial to achieving herd immunity. In a pandemic-weary society, the ability to discontinue nonpharmacologic control measures such as masking and social distancing may provide strong incentive for people to accept vaccination. Unknowns regarding the impact of vaccination on asymptomatic infection could result in prolonged precautionary measures which could dampen public willingness to receive the vaccine. Our findings provide evidence that mRNA COVID-19 vaccines are highly effective in working adults outside the controlled conditions of clinical trials.

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. The Lancet Public Health

The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine-United States

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Preprints with The Lancet

A Framework for Sustainable Contact Tracing and Exposure Investigation for Large Health Systems

An interactive web-based dashboard to track COVID-19 in real time

Mayo Clinic's Multidisciplinary Approach to Covid-19 Vaccine Allocation and Distribution. NEJM Catalyst Innovations in Care Delivery

Bayesian estimation of vaccine efficacy

M a n u s c r i p t